|
|
||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
1 Department of Pathology, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania 15213; and 2 Critical Care Medicine Department, National Institutes of Health, Bethesda, Maryland 20892
In an effort to understand the role
of key eicosanoid-forming enzymes in the activation of peroxisome
proliferator-activated receptor (PPAR), this study was designed to
evaluate the possible contributions of cytosolic phospholipase
A2 (cPLA2) and group IIA secretory
phospholipase A2 (sPLA2) in the regulation of
PPAR-mediated gene transcription in a human hepatoma cell line (HepG2).
The HepG2 cells express both PPAR-
and -
but not PPAR-
.
Overexpression of cPLA2, but not group IIA
sPLA2 in the HepG2 cells, caused a significantly increased
PPAR-
/
-mediated reporter activity. Antisense inhibition of
cPLA2 resulted in a significantly decreased PPAR-
/
activity. The PPAR-
/
-induced gene transcription in the HepG2 cells was inhibited by the cPLA2 inhibitors methyl
arachidonyl fluorophosphonate and arachidonyltrifluoromethyl ketone,
but not by the sPLA2 inhibitor LY311727. The expression of
PPAR-
-mediated endogenous gene apolipoprotein A-II was increased in
cells with overexpression of cPLA2, decreased in cells with
antisense inhibition of cPLA2, but unaltered in cells with
overexpression of group IIA sPLA2. The above results
demonstrated an important role of cPLA2, but not group IIA
sPLA2 in the control of PPAR activation. The
cPLA2-mediated PPAR activation was likely mediated by
arachidonic acid and prostaglandin E2. This study reveals a
novel intracellular function of cPLA2 in PPAR activation in
HepG2 cells. The cPLA2 thus may represent a potential
therapeutic target for the control of PPAR-related liver and metabolic
disorders such as obesity, lipid metabolic disorders, diabetes
mellitus, and atherosclerosis.
HepG2 cell; liver; arachidonic acid; prostaglandin; peroxisome proliferator response element
This article has been cited by other articles:
![]() |
L. Xu, C. Han, K. Lim, and T. Wu Cross-talk between Peroxisome Proliferator-Activated Receptor {delta} and Cytosolic Phospholipase A2{alpha}/Cyclooxygenase-2/Prostaglandin E2 Signaling Pathways in Human Hepatocellular Carcinoma Cells Cancer Res., December 15, 2006; 66(24): 11859 - 11868. [Abstract] [Full Text] [PDF] |
||||
![]() |
L. Xu, C. Han, and T. Wu A Novel Positive Feedback Loop between Peroxisome Proliferator-activated Receptor-{delta} and Prostaglandin E2 Signaling Pathways for Human Cholangiocarcinoma Cell Growth J. Biol. Chem., November 10, 2006; 281(45): 33982 - 33996. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. Han, A. J. Demetris, Y. Liu, J. H. Shelhamer, and T. Wu Transforming Growth Factor-{beta} (TGF-{beta}) Activates Cytosolic Phospholipase A2{alpha} (cPLA2{alpha})-mediated Prostaglandin E2 (PGE)2/EP1 and Peroxisome Proliferator-activated Receptor-{gamma} (PPAR-{gamma})/Smad Signaling Pathways in Human Liver Cancer Cells: A NOVEL MECHANISM FOR SUBVERSION OF TGF-{beta}-INDUCED MITOINHIBITION J. Biol. Chem., October 22, 2004; 279(43): 44344 - 44354. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. A. Caro and A. I. Cederbaum Role of Phospholipase A2 Activation and Calcium in CYP2E1-dependent Toxicity in HepG2 Cells J. Biol. Chem., September 5, 2003; 278(36): 33866 - 33877. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
| Visit Other APS Journals Online |